{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:33:08Z","timestamp":1790271188615,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12325-022-02084-7","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T05:02:48Z","timestamp":1651122168000},"page":"2932-2945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database"],"prefix":"10.1007","volume":"39","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Germino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"2084_CR1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273\u201384.","journal-title":"Lancet"},{"key":"2084_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jaad.2005.10.008","volume":"54","author":"PJ Mease","year":"2006","unstructured":"Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54:685\u2013704.","journal-title":"J Am Acad Dermatol"},{"key":"2084_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5114\/reum.2018.79501","volume":"56","author":"M Krajewska-Wlodarczyk","year":"2018","unstructured":"Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A, Placek W. Sleep disorders in patients with psoriatic arthritis and psoriasis. Reumatologia. 2018;56:301\u20136.","journal-title":"Reumatologia"},{"key":"2084_CR4","first-page":"680","volume":"35","author":"S Lee","year":"2010","unstructured":"Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35:680\u20139.","journal-title":"P T"},{"key":"2084_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"key":"2084_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"2084_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","volume":"73","author":"AP Villani","year":"2015","unstructured":"Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"2084_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/annrheumdis-2021-eular.4091","volume":"80","author":"LC Coates","year":"2021","unstructured":"Coates LC, Soriano E, Corp N, et al. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations 2021. Ann Rheum Dis. 2021;80(Suppl 1):139\u201340.","journal-title":"Ann Rheum Dis"},{"key":"2084_CR9","first-page":"700","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"2084_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rhematol. 2019;71:5\u201332.","journal-title":"Arthritis Rhematol"},{"key":"2084_CR11","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","volume":"59","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59:i37\u201346.","journal-title":"Rheumatology (Oxford)"},{"key":"2084_CR12","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525\u201336.","journal-title":"N Engl J Med"},{"key":"2084_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537\u201350.","journal-title":"N Engl J Med"},{"key":"2084_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","volume":"7","author":"P Nash","year":"2020","unstructured":"Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL Balance, an open-label, long-term extension study. Rheumatol Ther. 2020;7:553\u201380.","journal-title":"Rheumatol Ther"},{"key":"2084_CR15","unstructured":"Pfizer Inc. Xeljanz\u00ae (tofacitinib): highlights of prescribing information. 2020. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959. Accessed 14 Oct 2021."},{"key":"2084_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33:213.","journal-title":"J Korean Med Sci"},{"key":"2084_CR17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763\u201374.","journal-title":"Adv Ther"},{"key":"2084_CR18","first-page":"1073","volume":"25","author":"SL Canfield","year":"2019","unstructured":"Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the wild west of medication adherence reporting in specialty pharmacy. J Manag Care Spec Pharm. 2019;25:1073\u20137.","journal-title":"J Manag Care Spec Pharm"},{"key":"2084_CR19","doi-asserted-by":"publisher","unstructured":"Michelsen B, Georgiadis S, Di Giuseppe D, et al. Real-world 6 and 12-month drug retention, remission and response rates of secukinumab in 2,017 psoriatic arthritis patients in 13 European countries. Arthritis Care Res (Hoboken). 2021. https:\/\/doi.org\/10.1002\/acr.24560.","DOI":"10.1002\/acr.24560"},{"key":"2084_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3899\/jrheum.190815","volume":"48","author":"ML Thomas","year":"2021","unstructured":"Thomas ML, Shaddick G, Charlton R, et al. Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases. J Rheumatol. 2021;48:48\u201357.","journal-title":"J Rheumatol"},{"key":"2084_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00296-019-04345-1","volume":"39","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Accortt NA, Rebello S, et al. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. Rheumatol Int. 2019;39:1547\u201358.","journal-title":"Rheumatol Int"},{"key":"2084_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/09546634.2012.755255","volume":"24","author":"M Bonafede","year":"2013","unstructured":"Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24:369\u201373.","journal-title":"J Dermatolog Treat"},{"key":"2084_CR23","doi-asserted-by":"publisher","first-page":"e001519","DOI":"10.1136\/rmdopen-2020-001519","volume":"7","author":"R Ramonda","year":"2021","unstructured":"Ramonda R, Lorenzin M, Carriero A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021;7:e001519.","journal-title":"RMD Open"},{"key":"2084_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fmed.2020.00288","volume":"7","author":"K Klavdianou","year":"2020","unstructured":"Klavdianou K, Lazarini A, Grivas A, et al. Real life efficacy and safety of secukinumab in biologic-experienced patients with psoriatic arthritis. Front Med (Lausanne). 2020;7:288.","journal-title":"Front Med (Lausanne)"},{"issue":"Suppl 1","key":"2084_CR25","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1136\/annrheumdis-2020-eular.982","volume":"79","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Schmerold L, Tillett W, Germino R, Cappelleri JC, Young P. Demographic, treatment and disease characteristics of patients with psoriatic arthritis receiving tofacitinib in the United States, France, Germany, Italy, Spain and the United Kingdom. Ann Rheum Dis. 2020;79(Suppl 1):1707\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2084_CR26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2147\/PPA.S167508","volume":"12","author":"MJ Murage","year":"2018","unstructured":"Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483\u2013503.","journal-title":"Patient Prefer Adherence"},{"key":"2084_CR27","doi-asserted-by":"publisher","first-page":"e001671","DOI":"10.1136\/rmdopen-2021-001671","volume":"7","author":"V Stouten","year":"2021","unstructured":"Stouten V, Pazmino S, Verschueren P, et al. Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. RMD Open. 2021;7:e001671.","journal-title":"RMD Open"},{"key":"2084_CR28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/art.40789","volume":"71","author":"YC Lee","year":"2019","unstructured":"Lee YC, Kremer J, Guan H, Greenberg J, Solomon DH. Chronic opioid use in rheumatoid arthritis: prevalence and predictors. Arthritis Rheumatol. 2019;71:670\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"2084_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2020-eular.2587","volume":"79","author":"O Palsson","year":"2020","unstructured":"Palsson O, Love T, Wallman JK, Kapetanovic MC, Gunnarsson PS, Gudbjornsson B. Initiating TNF inhibitors in inflammatory arthritis does not decrease the average opioid analgesic consumption. Ann Rheum Dis. 2020;79(Suppl 1):58\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2084_CR30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/03007995.2020.1754186","volume":"36","author":"JA Walsh","year":"2020","unstructured":"Walsh JA, Cai Q, Lin I, Fitzgerald T, Pericone CD, Chakravarty SD. Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin. 2020;36:1245\u201352.","journal-title":"Curr Med Res Opin"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02084-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:38:19Z","timestamp":1653043099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02084-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2084"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02084-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}